RecruitingPhase 1NCT05995028

Universal 4SCAR7U Targeting CD7-positive Malignancies

Safety and Efficacy of Universal 4SCAR7U T Cell Therapy Targeting CD7-positive Hematological Malignancies

Sponsor

Shenzhen Geno-Immune Medical Institute

Enrollment

30 participants

Start Date

Oct 31, 2023

Study Type

INTERVENTIONAL

Conditions

Acute Myeloid Leukemia T-cell Acute Lymphoblastic Leukemia T-cell Acute Lymphoblastic Lymphoma

Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T cells based on 4SCAR7U design against CD7-positive hematological malignancies using CD7 specific universal CAR T cells. The study also aims to learn more about the function of CD7 targeting CAR T cells and their persistence in patients of hematological malignancies.

Eligibility

Min Age: 6 MonthsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new type of immune cell therapy called CAR-T (engineered immune cells programmed to attack cancer) for blood cancers that have a protein called CD7 on their surface. This is a "universal" therapy, meaning it does not need to come from the patient's own cells. **You may be eligible if...** - You are at least 6 months old - Your cancer cells have been confirmed to have the CD7 protein on their surface - You are in reasonably good health (Karnofsky score above 80) with a life expectancy over 3 months - Your heart, liver, and kidney function meet the study's safety thresholds **You may NOT be eligible if...** - Your cancer does not express the CD7 protein - You are in poor overall health or have less than 3 months life expectancy - Your organ function (heart, liver, kidney) is too impaired for the therapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALUniversal CD7-specific CAR gene-engineered T cells

Infusion of 4SCAR7U T cells

Locations(1)

Shenzhen Geno-immune Medical Institute

Shenzhen, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05995028

Related Trials

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

NCT06317649220 locations

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

NCT05554393177 locations

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390346 locations

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

NCT05554406220 locations

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

NCT063903193 locations